Professor Sang-Wook Yoon (Department of Radiology) of the CHA Medical Center in Korea and team. Professor Sang-Wook Yoon is globally known for uterine fibroid treatment.
A woman in her mid-30 who was soon to be married visited a radiologist. She was unexpectedly diagnosed with a uterine fibroid that needed to be immediately treated. She was told that she might have to undergo surgery because of its large-size. Fortunately, through the MR scan, it was discovered that the fibroid’s size and location made it possible to be treated without surgery.
Professor Sang-Wook Yoon (Department of Radiology) of the CHA Medical Center in Korea, who performed the medical procedure on this woman, said, “It was approximately 10cm in size, which is considered fairly large, and the patient was suffering from various symptoms, such as menstrual pain and internal bleeding. I felt a huge responsibility when she told me she had delayed her wedding because of the treatment. At a checkup three months after the surgery I saw her smile, and only then could I take a load off my mind.”
The patient’s fibroid had been reduced in size by more than half, and as a result, her symptoms had almost vanished.
Most uterine fibroidsare benign tumors, which do not require a special treatment. However, when a uterine fibroid causes severe pain, a patient has to decide on the proper method of treatment among various options including surgery, hormone therapy, etc. The solution in this case was ExAblate.
ExAblate is a MRgFUS (MR Guided Focused Ultrasound) technology that engages high intensity ultrasound beams to heat and destroy fibroid tissue. ExAblate was developed by InSightec and is installed on GE Healthcare’s Magnetic Resonance scanners. The procedure is the only non-invasive method approved by the US FDA for the treatment of uterine fibroids. In May 2011, CHA Medical Center became the first medical institution in the world to treat more than 500 patients using ExAblate.
Professor Sang-Wook Yoon is globally known for uterine fibroid treatment. He was listed on the top three biographical dictionaries: Marquis Who’s Who, IBC and ABI last year.
Since the first procedure in August 2006, he finally achieved completion of 500 cases on May 9, 2011. Professor Yoon said, “In the case of female patients, I believe that whether the uterus can be safely preserved or not should be the priority in choosing the method of treatment.”
ExAblate is being studied for use in various fields. In Korea, use of ExAblate is permitted only for uterine fibroids, except in cases of clinical research.
“ExAblate can be applied to studies of diseases for which invasive treatment can be dangerous, such as metastatic carcinoma, prostate cancer and neurological disorders. ExAblate will provide more options for women who need treatment,” said professor Yoon.
Since the first procedure in August 2006, Professor Sang-Wook Yoon finally achieved completion of 500 cases on May 9, 2011